Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2011-02-24

FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for KALETRA (lopinavir/ritonavir), updating its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kaletra (lopinavir)

Snippet

SUPPL AP for KALETRA (LOPINAVIR AND RITONAVIR)